Your browser doesn't support javascript.
loading
A comprehensive study of mutation and phenotypic heterogeneity of childhood mitochondrial leukodystrophies.
Hosseinpour, Sareh; Razmara, Ehsan; Heidari, Morteza; Rezaei, Zahra; Ashrafi, Mahmoud Reza; Dehnavi, Ali Zare; Kameli, Reyhaneh; Bereshneh, Ali Hosseini; Vahidnezhad, Hassan; Azizimalamiri, Reza; Zamani, Zahra; Pak, Neda; Rasulinezhad, Maryam; Mohammadi, Bahram; Ghabeli, Homa; Ghafouri, Mohammad; Mohammadi, Mahmoud; Zamani, Gholam Reza; Badv, Reza Shervin; Saket, Sasan; Rabbani, Bahareh; Mahdieh, Nejat; Ahani, Ali; Garshasbi, Masoud; Tavasoli, Ali Reza.
Affiliation
  • Hosseinpour S; Department of Pediatric Neurology, Vali-e-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Razmara E; Australian Regenerative Medicine Institute, Monash University, Clayton, VIC, 3800, Australia.
  • Heidari M; Myelin Disorders Clinic, Division of Pediatric Neurology, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Rezaei Z; Myelin Disorders Clinic, Division of Pediatric Neurology, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Ashrafi MR; Myelin Disorders Clinic, Division of Pediatric Neurology, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Dehnavi AZ; Myelin Disorders Clinic, Division of Pediatric Neurology, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran; Department of Physiology and Biomedical Engineering, Mayo Clinic College of Medicine and Science, Rochester, MN 55905, USA.
  • Kameli R; Department of Cell and Molecular Biology & Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran.
  • Bereshneh AH; Prenatal Diagnosis and Genetic Research Center, Dastgheib Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Vahidnezhad H; Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, USA; Department of Pediatrics, The University of Pennsylvania School of Medicine, Philadelphia, USA.
  • Azizimalamiri R; Department of Pediatric Neurology, Golestan Medical, Educational, and Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
  • Zamani Z; MD, MPH, Community Medicine Specialist, Tehran University of Medical Sciences, Tehran, Iran.
  • Pak N; Department of Radiology, Children's Hospital Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Rasulinezhad M; Myelin Disorders Clinic, Division of Pediatric Neurology, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Mohammadi B; Myelin Disorders Clinic, Division of Pediatric Neurology, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Ghabeli H; Myelin Disorders Clinic, Division of Pediatric Neurology, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Ghafouri M; Myelin Disorders Clinic, Division of Pediatric Neurology, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Mohammadi M; Pediatric Neurology Division, Children's Medical Center, Pediatrics Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran.
  • Zamani GR; Pediatric Neurology Division, Children's Medical Center, Pediatrics Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran.
  • Badv RS; Pediatric Neurology Division, Children's Medical Center, Pediatrics Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran.
  • Saket S; Iranian Child Neurology Center of Excellence, Pediatric Neurology Research Center, Research Institute for Children Health, Mofid Children's and Shohada-e Tajrish Hospitals, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Rabbani B; Growth and Development Research Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Mahdieh N; Growth and Development Research Center, Tehran University of Medical Sciences, Tehran, Iran; Cardiogenetic Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.
  • Ahani A; Mendel Medical Genetics Laboratory, Iran University of Medical Sciences, Tehran, Iran.
  • Garshasbi M; Department of Medical Genetics, Faculty of Medical Sciences, Jalal-Al Ahmad Hwy, Tarbiat Modares University, Tehran, Iran. Electronic address: masoud.garshasbi@modares.ac.ir.
  • Tavasoli AR; Myelin Disorders Clinic, Division of Pediatric Neurology, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran; Neurology Division, Barrow Neurological Institute, Phoenix Children's Hospital, Phoenix, AZ, USA. Electronic address: atavasoli@phoenixchildrens.org.
Brain Dev ; 46(4): 167-179, 2024 Apr.
Article in En | MEDLINE | ID: mdl-38129218
ABSTRACT

OBJECTIVE:

Mitochondrial leukodystrophies (MLs) are mainly caused by impairments of the mitochondrial respiratory chains. This study reports the mutation and phenotypic spectrum of a cohort of 41 pediatric patients from 39 distinct families with MLs among 320 patients with a molecular diagnosis of leukodystrophies.

METHODS:

This study summarizes the clinical, imaging, and molecular data of these patients for five years.

RESULTS:

The three most common symptoms were neurologic regression (58.5%), pyramidal signs (58.5%), and extrapyramidal signs (43.9%). Because nuclear DNA mutations are responsible for a high percentage of pediatric MLs, whole exome sequencing was performed on all patients. In total, 39 homozygous variants were detected. Additionally, two previously reported mtDNA variants were identified with different levels of heteroplasmy in two patients. Among 41 mutant alleles, 33 (80.4%) were missense, 4 (9.8%) were frameshift (including 3 deletions and one duplication), and 4 (9.8%) were splicing mutations. Oxidative phosphorylation in 27 cases (65.8%) and mtDNA maintenance pathways in 8 patients (19.5%) were the most commonly affected mitochondrial pathways. In total, 5 novel variants in PDSS1, NDUFB9, FXBL4, SURF1, and NDUSF1 were also detected. In silico analyses showed how each novel variant may contribute to ML pathogenesis.

CONCLUSIONS:

The findings of this study suggest whole-exome sequencing as a strong diagnostic genetic tool to identify the causative variants in pediatric MLs. In comparison between oxidative phosphorylation (OXPHOS) and mtDNA maintenance groups, brain stem and periaqueductal gray matter (PAGM) involvement were more commonly seen in OXPHOS group (P value of 0.002 and 0.009, respectively), and thinning of corpus callosum was observed more frequently in mtDNA maintenance group (P value of 0.042).
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: DNA, Mitochondrial / Mitochondria Limits: Child / Humans Language: En Journal: Brain Dev Year: 2024 Document type: Article Affiliation country: Irán

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: DNA, Mitochondrial / Mitochondria Limits: Child / Humans Language: En Journal: Brain Dev Year: 2024 Document type: Article Affiliation country: Irán